Latest Conference Articles

Tanezumab, a monoclonal antibody that targets nerve-growth factor, reduced pain in three common pain conditions.

Recent court rulings have grown in prominence because the Obama administration has taken a more tolerant stance toward the use of medical marijuana.

The efforts by the government to thwart drug abusers have dramatically increased the chances that a physician will face criminal complaints.

Sign up now for a reminder about our live coverage of the conference.

A study shows that XELOX improves disease-free survival rates for elderly patients with advanced-staged colorectal cancer.

Panitumumab plus chemotherapy significantly improved survival in patients with metastatic colorectal cancer, compared with chemotherapy alone.

Colorectal cancer patients who had wild-type (normal) KRAS gene status, but mutations in the BRAF, had a poor prognosis in spite of treatment with cetuximab.

Patients with high intake of polyamines found in orange juice, corn, red meat, peas and nuts had larger, more advanced adenomas on colonoscopy screening.

For patients with pancreatic cancer, an inhibitor of the insulin-like growth factor receptor led to response rates or stable disease in a majority of patients.

Patients with these two variations experienced recurrence more than three times sooner than those without it.

Sunitinib, approved to treat renal cell carcinoma and gastrointestinal stromal tumors, boosts survival rates in patients with neuroendocrine pancreatic tumors.

The TN category of disease significantly impacts survival, relapse, and colostomy failure in patients with anal cancer treated with concurrent chemoradiation.

Sorafenib was beneficial in advanced hepatocellular carcinoma patients, but failed to improve outcomes when given after transarterial chemoembolization.

The ASCO Cancer Foundation Merit Awards are designed to promote clinical cancer research by young scientists.

Resection via the abdominal and transhiatal approach is superior to the left thoracoabdominal approach for cardia and subcardia tumors.

Gastric cancer patients with positive peritoneal cytology who convert to negative cytology after systemic chemotherapy see a great improvement in survival.

A novel blood test identifies PAM4 (or clivatuzumab), an antigen that is present in almost 90% of pancreatic cancers and precancers.

To improve early detection of colorectal cancer and adenomas, when survival chances are greatest, researchers tried develop a reliable blood test for detection.

A study recommends use of trastuzumab concurrently with the taxane portion of chemotherapy for breast cancer patients.

In the BIG 1-98 trial, high-risk patients did best with 5 years of letrozole and low-risk patients did similarly well with any of the trial%u2019s regimens.

Many patients who chose mastectomy were not at increased breast-cancer risk and may have done so based on a failed attempt at breast-conservation surgery.

Anthracycline chemotherapy plus trastuzumab outperformed anthracycline alone, and performed similarly to a non-anthracycline regimen in breast cancer patients.

For patients with early breast cancer, peripheral neurotoxicity is an unfortunate side effect of treatment with taxanes, but there may be a silver lining.

Doubling the dose of fulvestrant increases the time to disease progression in the treatment of postmenopausal women with breast cancer.

The multi-targeted kinase inhibitor sorafenib, approved to treat kidney and liver cancer, may also benefit patients with metastatic breast cancer.

About 10 months of neoadjuvant letrozole is optimal for breast-conserving surgery in patients with early breast cancer.

Updated results confirm that addition of bevacizumab to docetaxel as first-line breast cancer treatment improves survival and response rates.

Lung cancer deaths are significantly less common in breast cancer patients who are treated with anti-estrogens.

Sorafenib showed promise when combined with chemotherapy for locally advanced or metastatic breast cancer.

Adding bevacizumab to chemotherapy improved survival compared with chemotherapy alone in breast cancer patients.